NADAC acquisition cost data for ACID CONTROLLER 20 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | Famotidine |
| Brand Name | Acid Controller |
| Manufacturer | Walgreen Company |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Pharmacologic Class | Histamine-2 Receptor Antagonist |
| Product Type | HUMAN OTC DRUG |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 63868048625 | $0.1542 | 2022-08-17 | OTC |
Generic: Famotidine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $74.7M | 6,038,190 | 1,919,087 | $0.1797 |
| 2020 | $143.5M | 8,676,615 | 2,604,222 | $0.2224 |
| 2021 | $201.0M | 10,633,192 | 2,999,285 | $0.2372 |
| 2022 | $181.5M | 11,671,755 | 3,301,424 | $0.1948 |
| 2023 | $202.8M | 12,748,534 | 3,593,191 | $0.2030 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.